ReutersReuters

Biotech Replimune's Q1 net loss widens, cash balance drops

RefinitivBacaan kurang dari 1 minit

Overview

  • Replimune fiscal Q1 net loss widens to $86.7 mln from $53.8 mln yr ago

  • Company's cash position decreased to $403.3 mln due to clinical development costs

Outlook

  • Replimune expects cash to fund operations into Q4 2026

Result Drivers

  • R&D EXPENSES - Increased due to scaling operations for RP1 commercial launch and higher personnel-related costs

  • SG&A EXPENSES - Rose significantly due to increased personnel and stock-based compensation costs

  • CASH DECREASE - Cash position fell due to clinical development costs and operating activities

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$86.69 mln

Q1 Basic EPS

-$0.95

Q1 Cash & Investments

$403.30 mln

Q1 Operating Expenses

$90.42 mln

Q1 Operating Income

-$90.42 mln

Press Release:

Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini